Inflammatory diseases of the gut

Journal of Medicinal Food

Volumn 21, Issue 2, 2018, Pages 113-126

  Rohr, Michael ^a   Narasimhulu, Chandrakala Aluganti ^a   Sharma, Dhara ^a   Doomra, Mitsushita ^a   Riad, Aladdin ^a   Naser, Saleh ^a   Parthasarathy, Sampath ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Crohn's disease; inflammation; microbiome; ulcerative colitis

Indexed keywords

FOOD INGREDIENT;

ARTICLE; CLINICAL FEATURE; CLINICAL OUTCOME; CROHN DISEASE; ENVIRONMENTAL FACTOR; GENETICS; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; NUTRITION; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; ULCERATIVE COLITIS; ANIMAL; GASTROINTESTINAL TRACT; HUMAN; IMMUNOLOGY; METABOLISM;

ANIMALS; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 85042235496     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2017.0138     Document Type: Article

References (183)

1. Kraft SC, Kirsner JB: Ulcerative colitis. In: Immunological Disease, 2nd edition. (Talmage DW, Rose B, Sherman WB, Vaughan JH, eds.). Little, Brown and Company, Boston, 1971, pp. 1346-1366.
2. Malik TA: Inflammatory bowel disease: historical perspective, epidemiology, and risk factors. Surg Clin North Am 2015;95: 1105-1122.
3. Duricova D, Pedersen N, Elkjaer M, et al.: Overall and causespecific mortality in Crohn's disease: A meta-analysis of population-based studies. Inflamm Bowel Dis 2010;16:347-353.
4. Baumgart DC, Sandborn WJ: Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet 2007;369:1641-1657.
5. Bach SP, Mortensen NJ: Chronic ulcerative colitis. In: Colorectal Surgery. (Bland KI et al. ed.). Pleasanton, CA: Baishideng Publishing Group Co., 2011. pp. 23-47.
6. Podolsky DK: Inflammatory bowel disease. N Engl J Med 2002; 347:417-429.
7. Strober W, Fuss I, Mannon P: The fundamental basis of inflammatory bowel disease. J Clin Invest 2007;117:514-521.
8. Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-434.
9. Sewell GW, Marks DJB, Segal AW: The immunopathogenesis of Crohn's disease: A three-stage model. Curr Opin Immunol 2009;21:506-513.
10. Papadakis KA, Targan SR: Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000;51: 289-298.
11. Targan SR, Hanauer SB, van Deventer SJ, et al.: A short term study of chimeric monoclonal antibody CA2 to tumor necrosis factor alpha for Crhon's disease. Crohn's Disease cA2 study Group. N Eng J Med 1997;337:1020.
12. Breese EJ, Michie CA, Nicholls SW, et al.: Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106: 1455-1466.
13. Hendrickson BA, Gokhale R, Cho JA: Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002;15:79-94.
14. Rowe WA, Anand BS. Inflammatory bowel disease clinical presentation drugs and diseases. Gastroenterology 2017:179037.
15. Mamula P, Markowitz JE, Baldassano RN: Inflammatory bowel disease in early childhood and adolescence: Special considerations. Gastroenterol Clin North Am 2003;32:967-995.
16. Spiller RC: Anorexia, nausea, vomiting, and pain ABC of the upper gastrointestinal tract. BMJ. 2001;323:1354-1357.
17. Sinicrope FA: Ileus and bowel obstruction Holland-Frei. In: Kufe DW, Pollock RE, Weichselbaum RR, et al. (eds). Cancer Medicine, 6th edition. Hamilton (ON): BC Decker Inc., 2003.
18. Levine JS, Burakoff R: Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2011;7: 235-241.
19. Kaplan GG: The global burden of IBD: From 2015 to 2025. Nat Rev Gastroenterol Hepatol 2015;12:720-727.
20. Loftus EV: Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-1517.
21. Ng SC: Epidemiology of inflammatory bowel disease: Focus on Asia. Best Pract Res Clin Gastroenterol 28 (2014) 363-372.
22. Bernstein CN, Shanahan F: Disorders of a modern lifestyle: Reconciling the epidemiology of inflammatory bowel diseases. Gut 2008;57:1185-1191.
23. Ko Y, Butcher R, Leong RW: Epidemiological studies of migration and environmental risk factors in the inflammatory bowel diseases. World J Gastroenterol 2014;20:1238-1247.
24. Pinsk V, Lemberg DA, Grewal K, et al.: Inflammatory bowel disease in the South Asian pediatric population of British Columbia. Am J Gastroenterol 2007;102:1077-1083.
25. Ananthakrishnan AN, Binion DG: Treatment of ulcerative colitis in the elderly. Dig Dis 2009;27:327-334.
26. Wine E, Reif SS, Leshinsky-Silver E, et al.: Pediatric Crohn's disease and growth retardation: The role of genotype, phenotype, and disease severity. Pediatrics 2004;114:1281-1286.
27. Benchimol EI, Guttmann A, Griffiths AM, et al.: Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: Evidence from health administrative data. Gut 2009; 58:1490-1497.
28. Molodecky NA, Kaplan GG: Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2010;6: 339-346.
29. Actis GC, Pellicano R, Fadda M, Rosina F: Antibiotics and nonsteroidal anti-inflammatory drugs in outpatient practice: Indications and unwanted effects in a gastroenterological setting. Curr Drug Saf 2014;9:133-137.
30. Dubeau MF, Iacucci M, Beck PL, et al.: Drug-induced inflammatory bowel disease and IBD-like conditions. Inflamm Bowel Dis 2013;19:445-456.
31. Brunekreef B, Holgate ST: Air pollution and health. Lancet 2002;360:1233-1242.
32. Peters A, Dockery DW, Muller JE, et al.: Increased particulate air pollution and the triggering of myocardial infarction. Circulation 2001;103:2810-2815.
33. Hart JE, Laden F, Puett RC, et al.: Exposure to traffic pollution and increased risk of rheumatoid arthritis. Environ Health Perspect 2009;117:1065-1069.
34. Kaplan GG, Dixon E, Panaccione R, et al.: Air pollution and appendicitis: A Novel association. Am J Gastroenterol 2008; 103 (S1):P820.
35. Camara JA, Ziegler R, Begre S, Schoepfer AM, Kanel A: The role of psychological stress in inflammatory bowel disease: Quality assessment of methods of 18 prospective studies and suggestions for future research. Digestion 2009;80:129-139.
36. Jones DT, Osterman MT, Bewtra M, Lewis JD: Passive smoking and inflammatory bowel disease: A meta-analysis. Am J Gastroenterol 2008;103:2382-2393.
37. Parkes GC, Whelan K, Lindsay JO: Smoking in inflammatory bowel disease: Impact on disease course and insights into the etiology of its effect. J Crohns Colitis 2014;8:717-725.
38. Sender R, Fuchs S, Milo R: Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 2016;164:337-340.
39. Rojo D, Mendez-Garcia C, Anna B, Rafael R, Andres B, Manuel M, Barbas FC: Exploring the human microbiome from multiple perspectives: Factors altering its composition and function. FEMS Microbiol Rev 2017.
40. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, et al.: Changes in gut microbiota control metabolic endotoxemiainduced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008;57:1470-1481.
41. Ley RE, Turnbaugh PJ, Klein S, Gordon JI: Microbial ecology: Human gut microbes associated with obesity. Nature 2006;444: 1022-1023.
42. Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, et al.: Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A 2006;103:12511-12516.
43. Frank DN, Robertson CE, Hamm CM, Kpadeh Z, Zhang T, et al.: Disease phenotype and genotype are associated with shifts in intestinal associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2011;17:179-184.
44. Neufeld KM, Kang N, Bienenstock J, Foster JA: Reduced anxiety-like behavior and central neurochemical change in germfree mice. Neurogastroenterol Motil 2011;23:255-264, e119.
45. Chu FF, Esworthy RS, Chu PG, Longmate JA, Huycke MM, et al.: Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res 2004;64:962-968.
46. Sekirov I, Russell SL, Antunes CM, Brett B: Finlay gut microbiota in health and disease. Physiol Rev 2010;90:859-904.
47. Tannock GW: Effect of dietary and environmental stress on the gastrointestinal microbiota. In: Human Intestinal Microflora in Health and Disease (Hentges, DJ, ed.). Academic, London, 1983, p. 517.
48. Hentges DJ: The anaerobic micro flora of the human body. Clin Infect Dis 1993;16:S175-S180.
49. Hagiage M: The intestinal ora of balanced equilibrium [In French]. Paris: Vigot, 1994: 25.
50. Vollaard EJ, Clasener HAL, van Saene HKF, Muller NF: Effect on colonization resistance: An important criterion in selecting antibiotics. DICP 1990;24:60-66.
51. Reid G, Bruce AW, McGroarty JA, Cheng K-J, Costerton JW: Is there a role for lactobacilli in prevention of urogenital and intestinal infections? Clin Microbiol Rev 1990;3:335-344.
52. Hillier SL: The role of naturally occurring and exogenously supplied lactobacilli in the human vagina. Microb Ecol Health Dis 1998;10:193.
53. Flint HJ, Scott KP, Louis P, Duncan SH: The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol 2012;9:577-589.
54. Gerritsen J, Smidt H, Rijkers GT, Vos WM: Intestinal microbiota in human health and disease: The impact of probiotics. Genes Nutr 2011;6:209-240.
55. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Reddy DN: Role of the normal gut microbiota. World J Gastroenterol 2015;21:8787-8803.
56. Sartor RB: Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134: 577-594.
57. Sartor RB, Mazmanian SK: Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol 2012;1:15-21.
58. Geirnaert A, Calatayud M, Grootaert C, Laukens D, Devriese S, Smagghe G, De Vos M, Boon N, Van de Wiele T: Butyrateproducing bacteria supplemented in vitro to Crohn's disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity. Sci Rep 2017;7:11450.
59. Imhann F, Vila AV, Bonder MJ, Fu J, Gevers D, Visschedijk MC, Spekhorst LM, Alberts R, Franke L, van Dullemen HM, Ter Steege RWF, Huttenhower C, Dijkstra G, Xavier RJ, Festen EAM, Wijmenga C, Zhernakova A, Weersma RK: Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut 2016; pii:gutjnl-2016-312135.
60. Meisel M, Mayassi T, Fehlner-Peach H, Koval JC, O'Brien SL, Hinterleitner R, Lesko K, Kim S, Bouziat R, Chen L, Weber CR, Mazmanian SK, Jabri B, Antonopoulos DA: Interleukin-15 promotes intestinal dysbiosis with butyrate deficiency associated with increased susceptibility to colitis. ISME J 2017;11:15-30.
61. Hamer HM, et al.: Review article: The role of butyrate on colonic function. Aliment Pharm Therap 2008;27:104-119.
62. Van Immerseel F, et al.: Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. J Med Microbiol 2010;59:141-143.
63. Wang W, Chen L, Zhou R, et al.: Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrateproducing bacteria in inflammatory bowel disease. J Clin Microbiol 2014;52:398-406.
64. Sokol H, Pigneur B, Watterlot L, et al.: Faecalibacterium prausnitzii is an antiinflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008;105:16731-16736.
65. Takaishi H, Matsuki T, Nakazawa A, et al.: Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol 2008;298:463-472.
66. Andoh A, Imaeda H, Aomatsu T, et al.: Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol 2011;46:479-486.
67. Angelberger S, Reinisch W, Makristathis A, et al.: Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 2013;8:1620-1630.
68. Qazi T, Amaratunga T, Barnes EL, Fischer M, Kassam Z, Allegretti JR: The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and metaanalysis. Gut Microbes 2017;8:574-588.
69. Baker GD, Nieuwdorp M, et al.: Fecal microbiota transplantation: Therapeutic potential for a multitude of diseases beyond clostridium difficile. Microbiol Spectr 2017;5:1-14.
70. Fuentes S, van Nood E, Tims S, Heikamp-de Jong I, ter Braak CJ, Keller JJ, Zoetendal EG, de Vos WM: Reset of a critically disturbed microbial ecosystem: Faecal transplant in recurrent Clostridium difficile infection. ISME J 2014;8:1621-1633.
71. Khan KJ, Ullman TA, Ford AC, et al.: Antibiotic therapy in inflammatory bowel disease: A systematic review and metaanalysis. Am J Gastroenterol 2011;106:661-673.
72. Ellen S: Pierce1Ulcerative colitis and Crohn's disease: Is Mycobacterium avium subspecies paratuberculosis the common villain? Gut Pathog 2010;2:21.
73. Naser SA, Ghobrial G, Romero C, Valentine JF: Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet 2004;364: 1039-1044.
74. Feller M, Huwiler K, Stephan R: Mycobacterium avium subspecies paratuberculosis and Crohn's disease: A systematic review and meta-analysis. Lancet Infect Dis 2007;7:607-613.
75. Xia A, Stempak JM, Grist J, Bressler B, Silverberg MS, Bach H: Effect of inflammatory bowel disease therapies on immunogenicity of Mycobacterium paratuberculosis proteins. Scand J Gastroenterol 2014;49:157-163.
76. Selby W, Pavli P, Crotty B, et al.: Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007;132:2313-2319.
77. Kuenstner JT, Chamberlin W, Naser SA, et al.: Resolution of Crohn's disease and complex regional pain syndrome following treatment of paratuberculosis. World J Gastroenterol 2015;21: 4048-4062.
78. Ohkusa T, Sato N, Ogihara T, Morita K, Ogawa M, Okayasu I: Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol 2002;17:849-853.
79. Tahara T, Shibata T, Kawamura T, et al.: Fusobacterium detected in colonic biopsy and clinicopathological features of ulcerative colitis in Japan. Dig Dis Sci 2015;60:205-210.
80. Sokol H, Leducq V, Aschard H, et al.: Fungal microbiota dysbiosis in IBD. Gut 2017;66:1039-1048.
81. Standaert-Vitse A, Sendid B, Joossens M, et al.: Candida albicans colonization and ASCA in familial Crohn's disease. Am J Gastroenterol 2009;104:1745-1753.
82. Ksiadzyna D, Semianow-Wejchert J, Nawrot U, Wlodarczyk K, Paradowski L: Serum concentration of interleukin 10, antimannan Candida antibodies and the fungal colonization of the gastrointestinal tract in patients with ulcerative colitis. Adv Med Sci 2009;54:170-176.
83. Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, et al.: Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J 2007;1:403-418.
84. Kotlowski R, Bernstein CN, Sepehri S, Krause DO: High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 2007;56:669-675.
85. Martinez-Medina M, Aldeguer X, Lopez-Siles M, et al.: Molecular diversity of Escherichia coli in the human gut: New ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn's disease. Inflamm Bowel Dis 2009; 15:872-882.
86. Mei L, Targan SR, Landers CJ, et al.: Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology 2006;130: 1078-1085.
87. Mondot S, Kang S, Furet JP, et al.: Highlighting new phylogenetic specificities of Crohn's Disease microbiota. Inflamm Bowel Dis 2011;17:185-192.
88. Li J, Butcher J, Mack D, et al.: Functional impacts of the intestinal microbiome in the pathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 2015;21:139-153.
89. Clayton E, Rea M, Shanahan F, et al.: The vexed relationship between Clostridium difficile and inflammatory bowel disease: An assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 2009;104:1162-1169.
90. Shanahan F, Bernstein CN: The evolving epidemiology of inflammatory bowel disease. Gastroenterol 2009;25:301-305.
91. De Santis S, Cavalcanti E, Mastronardi M, Jirillo E, Chieppa M: Nutritional keys for intestinal barrier modulation. Front Immunol 2015;6:612.
92. Gourbeyre P, Denery S, Bodinier M: Probiotics, prebiotics, and synbiotics: Impact on the gut immune system and allergic reactions. J Leukoc Biol 2011;89:685-695.
93. Gill SR, Pop M, Deboy RT, et al.: Metagenomic analysis of the human distal gut microbiome. Science 2006;312:1355-1359.
94. Sawicki CM, Livingston KA, Obin M, Roberts SB, Chung M, McKeown NM: Dietary fiber and the human gut microbiota: Application of evidence mapping methodology. Nutrients 2017; 9:125.
95. Slavin J: Fiber and prebiotics: Mechanisms and health benefits. Nutrients 2013;5:1417-1435.
96. Lucendo AJ, Rezende LCD: Importance of nutrition in inflammatory bowel disease. World J Gastroenterol 2009;15: 2081-2088.
97. Round JL, Mazmanian SK: The gut microbiome shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009;9:313-323.
98. Reinagel M,Torelli J: The inflammation free diet plan. New York: McGraw-Hill Education, 2006.
99. Fontana L, Klein S: Aging, adiposity, and calorie restriction. JAMA 2007;297:986-994.
100. Huffman KM, Orenduff MC, Samsa GP, Houmard JA, Kraus WE, Bales CW: Dietary carbohydrate and high-sensitivity Creactive protein in at-risk women and men. Am Heart J 2007; 154:962-968.
101. Enos RT, Davis JM, Velazquez KT, et al.: Influence of dietary saturated fat content on adiposity, macrophage behavior, inflammation, and metabolism: Composition matters. J Lipid Res 2013;54:152-163.
102. Patterson E, Wall R, Fitzgerald GF, Ross RP, Stanton C: Health implications of high dietary omega-6 polyunsaturated fatty acids. J Nutr Metab 2012;1-9.
103. Van der Logt EM, Blokzijl T, van der Meer R, et al.: Westernized high-fat diet accelerates weight loss in dextran sulfate sodium-induced colitis in mice, which is further aggravated by supplementation of heme. J Nutr Biochem 2013;24:1159-1165.
104. Gruber L, Kisling S, Lichti P, et al.: High fat diet accelerates pathogenesis of murine Crohn's disease-like ileitis independently of obesity. PLoS One 2013;8:e71661.
105. Tjonneland A, Overvad K, et al.: Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: A nested case-control study within a European prospective cohort study. Gut 2009;58:1606-1611.
106. Pereira C, Gracio D, Teixeira JP, Magro F: Oxidative stress and DNA damage: Implications in inflammatory bowel disease. Inflamm Bowel Dis 2015;21:2403-2417.
107. Ananthakrishnan AN, Khalili H, Konijeti GG, et al.: A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology 2013; 145:970-977.
108. Werner T, Wagner SJ, Martinez I, et al.: Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis. Gut 2011;60:325-333.
109. Hentze MW, Muckenthaler MU, Galy B, et al.: Two to tango: Regulation of mammalian iron metabolism. Cell 2010;142: 24-38.
110. Costea I, Mack DR, Lemaitre RN, et al.: Interactions between the dietary polyunsaturated Fatty Acid ratio and genetic factors determine susceptibility to pediatric Crohn's disease. Gastroenterology 2014;146:929-931.
111. Korolkova OY, Myers JN, Pellom ST, Wang L, Koma AEM: Characterization of serum cytokine profile in predominantly colonic inflammatory bowel disease to delineate ulcerative and Crohn's colitides clin med insights. Gastroenterol 2015;8: 29-44.
112. Johansson J, Nilsson O, Stotzer PO: Colonoscopy and Sigmoidoscopy are equally effective for the diagnosis of colonic acute graft-versus-host disease in patients with diarrhea after allogeneic stem cell transplantation: A prospective controlled trial. Biol Blood Marrow Transplant 2015;21:2086-2090.
113. Mattar MC, Lough D, Pishvaian MJ, Charabaty A: Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res 2011;4:53-61.
114. Kuan LC1, Li YT, Chen FM, Tseng CJ, Wu SF, Kuo TC: Efficacy of treating abdominal wall pain by local injection. Taiwan. J Obstet Gynecol 2006;45:239-243.
115. Carter MJ, Lobo AJ, Travis SP: IBD Section of the British Society of Gastroenterology: Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl V): v1-v16.
116. Yamamoto T: Nutrition and diet in inflammatory bowel disease. Curr Opin Gastroenterol 2013;29:216-221.
117. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Rutgeerts P: Subcutaneous golimumab maintains clinical response in patients with moderateto-severe ulcerative colitis. Gastroenterology 2014;146:96-109.e1.
118. Sandborn WJ, Colombel JF, Enns R, Feagan BE, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, et al.: Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-1925.
119. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, et al.: Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-721.
120. Vermeire S, Sandborn WJ, Danese S, Hebuterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, Greguš M, Hellstern PA, et al.: Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): A phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2017;390:135-144.
121. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P, Sandborn WJ, et al.: A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135:1130-1141.
122. Keir M, Tew GW, Luca D, Eastham-Anderson J, Diehl L, Egen JG, Vermeire S, Mansfield JC, Lamb CA, Panes C, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, De Hertogh G, Kirby JA, Van Assche G, Rutgeerts P, O'Byrne S: OP010 AlphaE integrin expression as a predictive biomarker for induction of clinical remission by etrolizumab: Analysis of a phase II trial in moderate-to-severely active ulcerative colitis. J Crohns Colitis 2014;8:S7-S7.
123. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto Y: A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-996.
124. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W: Tofacitinib, an oral Janus Kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367:616-624.
125. Sands B, Sandborn W, Feagan BG, Lichtenstein G, Zhang H, Szapary P, Panes J, Vermeire S, O'Brien C, Dewey J, Yang Z, Johanns J, Strauss R, Marano C: PD-009A Phase 2B, multicenter, randomized, placebo-controlled dose-ranging trial of peficitinib, an oral JAK inhibitor, in patients with moderately-severely active UC. Inflamm Bowel Dis 2017;23:S8.
126. D'Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG, et al.: A phase II study of laquinimod in Crohn's disease. Gut 2015;64:1227-1235.
127. Sandborn WJ, Feagan B, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S: Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med 2016;374: 1754-1762.
128. Chebli K, Papon L, Paul C, Garcel A, Campos N, Scherrer D, Ehrlich J, Hahne M, Tazi J: The anti-Hiv candidate Abx464 dampens intestinal inflammation by triggering Il-22 production in activated macrophages. Sci Rep 2017;7:4860.
129. D'allard D, Gay J, Descarpentries C, Frisan E, Adam K, Verdier F, Floquet C, Dubreuil P, Lacombe C, Fontenay M, Mayeux P, Kosmider O: Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket. PLoS One 2013;8: e60961.
130. Monteleone G, Fantini MC, Onali S, Zorzi F, Sancesario G, Bernardini S, Calabrese E, Viti F, Monteleone I, Biancone L, Pallone F: Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther 2012;20:870-876.
131. Grip O, Janciauskiene S, Bredberg A: Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease. Br J Pharmacol 2008;155:1085-1092.
132. Liang HL, Ouyang Q: A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. World J Gastroenterol 2008;14:114-119.
133. Friedman G, George J: Treatment of refractory ''Pouchitis'' with prebiotic and probiotic therapy. Gastroenterology 2000; 118:A778.
134. Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M: Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-858.
135. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M: Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103-1108.
136. Art AL, Hendy P: The microbiome in inflammatory bowel disease and its modulation as a therapeutic manoeuvre. Proc Nutr Soc 2014;73:452-456.
137. Feagan BG, Macdonald JK: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10:CD000544.
138. Patel H, Barr A, Jeejeebhoy KN: MBBS, FRCPC3 Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol 2009;23:170-176.
139. Sutherland L, Macdonald JK: Oral 5-aminosalicylates for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;19:CD000544.
140. Ford AC, Bernstein CN, Khan KJ, et al.: Glucocorticosteroid therapy in inflammatory bowel disease: Systematic review and meta-analysis. Am J Gastroenterol 2011;106:590-599.
141. Friedman S, Lichtenstein GR: Ulcerative colitis. In: Therapy of Digestive Disorders, 2nd edition (Wolfe MM et al. eds.). Saunders Elsevier, Philadelphia, 2006, pp. 803-817.
142. Ferrante M, D'Hoore A, Vermeire S, et al.: Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009;15:1062-1070.
143. Alexander C: Wiseman immunosuppressive medications. Immunosuppressive drugs inhibit proliferation and activation of lymphocytes. I Clin J Am Soc Nephrol 2016;11:332-343.
144. Khan KJ, Dubinsky MC, Ford AC, et al.: Efficacy of immunosuppressive therapy for inflammatory bowel disease: A systematic review and meta-analysis. Am J Gastroenterol 2011; 106:630-642.
145. Chaparro M, Ordas I, Cabre E, et al.: Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients. Inflamm Bowel Dis 2013; 19: 1404-1410.
146. Treton X, Bouhnik Y, Mary JY, et al.: Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: A high risk of relapse. Clin Gastroenterol Hepatol 2009; 7:80-85.
147. Herfarth HH, Kappelman MD, Long, MD, Isaacs, KL. Use of methotrexate in the treatment of inflammatory bowel diseases (IBD). Inflamm Bowel Dis 2016;22:224-233.
148. Danes S, Fiorino G, Peyrin-Biroulet L: Biological agents for moderately to severely active ulcerative colitis: A systematic review and network meta-analysis. Ann Intern Med 2014;160: 704-711.
149. Nguyen DL, Flores S, Sassi K, Bechtold ML, Nguyen ET, Parekh NK: Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease. Ther Adv Chronic Dis 2015;6:147-154.
150. Calafiore A, Gionchetti P, Calabrese C, Tambasco R, Spuri-Fornarini G, Liguori G, Riso D, Campieri M, Rizzello F: Probiotics, prebiotics and antibiotics in the treatment of inflammatory bowel disease. J Gastroenterol Hepatol Res 2012;1: 97-106.
151. Triantafillidis JK, Merikas E, Georgopoulos F: Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther 2011;5:185-210.
152. Ramasundara M, Leach ST, Lemberg DA, Day AS: Defensins and inflammation: The role of defensins in inflammatory bowel disease. J Gastroenterol Hepatol 2009;24:202-208.
153. Sood A, Midha V, Makharia GK, et al.: The probiotic preparation, VSL#3 induces remission in patients with mild-tomoderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:1202-1209.
154. Lee B, Bak Y: Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil 2011;17:252-266.
155. Thomas C, Versalovic J: Probiotics-host communication: Modulation of signaling pathways in the intestine. Gut Microbes 2010;1:148-163.
156. Bron P, Van Baarlen P, Kleerebezem M: Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat Rev Microbiol 2011;10:66-78.
157. Hemarajata P, Versalovic J: Effects of probiotics on gut microbiota: Mechanisms of intestinal immunomodulation and neuromodulation. Therap Adv Gastroenterol 2013;6:39-51.
158. Garcia Vilela E, Lourdes D, Abreu D, Ferrari M, Gama OD, Torres H, et al.: Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol 2008;43:842-848.
159. Ochoa-Reparaz J, Mielcarz D, Begum-Haque S, Kasper L: Gut, bugs, and brain: Role of commensal bacteria in the control of central nervous system disease. Ann Neurol 2011;69:240-247.
160. Berer K, Mues M, Koutrolos M, Rasbi Z, Boziki M, Johner C, et al.: Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011;479:538-541.
161. Lavasani S, Dzhambazov B, Nouri M, Fak F, Buske S, Molin G, et al.: A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One 2010;5:e9009.
162. Sandhu BK, Fell JM, Beattie RM, et al.: Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 2010;1:1-13.
163. Forbesa A, Escherb J, Hebuternec X, K1ȩkd S, Krznarice Z, Schneiderc S, Shamirf R, Stardelovag K, Wierdsma N: ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clin Nutr 2017;36:321-347.
164. Levine A, Wine E: Effects of enteral nutrition on Crohn's disease: Clues to the impact of diet on disease pathogenesis. Inflamm Bowel Dis 2013;19:1322-1329.
165. Claesson MJ, Jeffery IB, Conde S, et al.: Gut microbiota composition correlates with diet and health in the elderly. Nature 2012;488:178-184.
166. Wall CL, Day AS, Gearry RB: Use of exclusive enteral nutrition in adults with Crohn's disease: A review. World J Gastroenterol 2013;19:7652-7660.
167. Halme L, Paavola-Sakki P, Turunen U, Lappalainen M, Färkkila M, Kontula K: Family and twin studies in inflammatory bowel disease. World J Gastroenterol 2006;12:3668-3672.
168. Tysk C, Lindberg E, Järnerot G, Floderus-Myrhed B: Ulcerative colitis and Crohn9s disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988;29:990-996.
169. Thompson NP, Driscoll R, Pounder RE, Wakefield AJ: Genetics versus environment in inflammatory bowel disease: Results of a British twin study. BMJ 1996;312:95.
170. Orholm MVB, Sørensen TIA, Rasmussen LP, Kyvik KO: Concordance of inflammatory bowel disease among Danish Twins: Results of a Nationwide study. Scand J Gastroenterol 2000;35:1075-1081.
171. Barrett JC, Hansoul S, Nicolae DL, et al.: Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008;40:955.
172. Hugot JP, Laurent-Puig P, Gower-Rousseau C, Olson JM, Lee JC, Beaugerie L, Naom I, Dupas JL, Van Gossum A, Orholm M, Bonaiti-Pellie C, Weissenbach J, Mathew CG, Lennard-Jones JE, Cortot A, Colombel JF, Thomas G: Mapping of a susceptibility locus for Crohn's disease on chromosome 16 Nature 1996;379:821.
173. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JHDuerr RH: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-1463.
174. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, et al.: Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 2015;47:979-986.
175. Zhang J, Wu J, Peng X, Song J, Wang J, Dong W: Associations between STAT3 rs744166 polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: A meta-analysis. PLoS One 2014;9:e109625.
176. Glas J, Seiderer J, Wagner J, Olszak T, Fries C, et al.: Analysis of IL12B gene variants in inflammatory bowel disease. PLoS One 2012;7:e34349.
177. Yamazaki K, McGovern D, Ragoussis J, Paolucci M, Butler H, Jewell D, Cardon L, Takazoe M, Tanaka T, Ichimori T, Saito S, Sekine A, Iida A, Takahashi A, Tsunoda T, Lathrop M, Nakamura Y: Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet 2005;14:3499-3506.
178. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, et al.: Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118.
179. Villani AC, Lemire M, Louis E, Silverberg MS, Collette C, Fortin G, Nimmo ER, Renaud Y, Brunet S, Libioulle C, Belaiche J, Bitton A, Gaudet D, Cohen A, Langelier D, Rioux JD, Arnott ID, Wild GE, Rutgeerts P, Satsangi J, Vermeire S, Hudson TJ, Franchimont D: Genetic variation in the familial Mediterranean Fever Gene (MEFV) and risk for Crohn's disease and ulcerative colitis. PLoS One 2009;4:e7154.
180. Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, Kwiatkowski DP, et al.: The wellcome trust case control consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-678.
181. Lees CW, Zacharias WJ, Tremelling M, Noble CL, Nimmo ER, Tenesa A, et al.: Analysis of germline GLI1 variation implicates hedgehog signalling in the regulation of intestinal inflammatory pathways. PLoS Med 2008;5:e239.
182. Croucher PJP, Mascheretti S, Hampe J, Huse K, Frenzel H, Stoll M, Lu T, Nikolaus S, Yang S, Krawczak M, Kim WH, Schreiber S: Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur J Hum Genet 2003;11:6-16.
183. Törkvist L, Noble CL, Lördal M, Sjöqvist U, Lindforss U, Nimmo ER, Russell RK, Löfberg R, Satsangi J: Contribution of CARD15 variants in determining susceptibility to Crohn's disease in Sweden. Scand J Gastroenterol 2006;41: 700-705.